The advent of anti-tumor necrosis factor (TNF)-α therapy has been a major advance in the medical management of Crohn's disease (CD). However, a significant proportion of patients with CD do not respond adequately to treatment with these agents. Primary and secondary nonresponse to anti-TNFα therapy represents a common clinical challenge, and highlights the need for the development of additional medication options for CD. The proinflammatory cytokines interleukin (IL)-12 and IL-23 are thought to play a key role in the pathogenesis of CD, and serve as a potential target for additional biologic therapies. Monoclonal antibodies targeting IL-12/23 have shown efficacy in animal models of colitis, and are currently being studied in Phase III clinical trials of CD. This review focuses on ustekinumab, a fully human immunoglobulin G 1 monoclonal antibody, which blocks activity of IL-12 and IL-23 through binding the p40 subunit, and describes the current efficacy and safety data for ustekinumab in patients with CD.
Introduction to Crohn's disease and current treatment options
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that is characterized by recurrent relapses and periods of remission. Current therapies are aimed at inducing and maintaining remission and improving quality of life (QOL), while minimizing adverse effects of pharmacologic therapy. Historically, corticosteroids were used as first-line therapy to manage symptoms, but were associated with a high incidence of steroid dependency and unacceptable rates of adverse events. 1 Furthermore, while corticosteroids are useful to induce symptomatic remission, they do not promote mucosal healing and are not useful for maintenance of remission. 1, 2 Methotrexate and thiopurines (6-mercaptopurine and azathioprine) were found to be effective as steroidsparing agents and for maintenance of remission in CD, [3] [4] [5] but have a delayed onset of action and are only effective in 60%-70% of patients who receive them. 4, 5 More recently, the tumor necrosis factor (TNF)-α antagonists infliximab and adalimumab have been shown to be effective for the induction and maintenance of remission in patients with moderate-to-severe CD, while certolizumab pegol is effective for the maintenance of remission in patients who have responded to certolizumab-induction therapy. [6] [7] [8] [9] [10] [11] [12] This class of medication is currently the most effective treatment option available for CD.
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14 Among patients who respond to induction therapy with an anti-TNFα agent, almost half lose response and/or develop hypersensitivity reactions (secondary nonresponders). 15 Patients with a primary nonresponse are unlikely to benefit from switching to a second anti-TNFα agent. Patients who develop a secondary nonresponse to an anti-TNFα agent also have lower response rates when switching to a second or third anti-TNFα agent. 16 This represents a common but challenging clinical problem, and emphasizes the need for additional therapies for the management of these patients.
Review of pharmacology, mode of action, pharmacokinetics of ustekinumab
The interleukin (IL)-12 family of cytokines, which includes IL-22, IL-23, IL-25, and IL-27, is responsible for the differentiation of T-helper (Th) cells into cytotoxic Th1 cells. [17] [18] [19] Inflammatory changes in CD are associated with excess cytokine activity driven by activated Th1 cells. 20, 21 Accordingly, IL-12 and IL-23 have been linked to the pathophysiology of CD as well as other immune-mediated disorders, including psoriasis, psoriatic arthritis, and multiple sclerosis. [21] [22] [23] IL-12 and IL-23 are heterodimeric proteins composed of a unique subunit (p35 or p19, respectively) covalently linked to a shared p40 subunit. 19, 24 IL-12 induces differentiation of naïve cluster of differentiation (CD)4 + T cells into interferon-γ-producing Th1 cells, which mediate cellular immunity. IL-23 induces differentiation of naïve CD4 + T cells into Th17 cells, which produce several proinflammatory cytokines to also mediate cellular immunity. 19, 25, 26 Therefore, inhibiting IL-12 and IL-23 inflammation pathways could potentially be a unique target for therapy in CD.
Ustekinumab (CNTO-1275, Stelara ® ; Janssen Biotech, Horsham, PA, USA) is a humanized immunoglobulin G 1 κ monoclonal antibody, which binds with high affinity and specificity to the shared p40 subunit of IL-12 and IL-23. This binding blocks the interaction of both IL-12 and IL-23 with their receptor IL-12Rβ1, 26, 27 and results in a diminution of immune-cell activation by inhibiting the action of T cells. Ustekinumab can be given intravenously (IV) or subcutaneously (SC) as a weight-based infusion or a fixed-dose injection. The median half-life of ustekinumab is approximately 3 weeks, and exposure is increased in a dose-proportional manner. 28 The pharmacokinetic profile is affected by body weight, but not by age. 28 Ustekinumab is currently approved by the US Food and Drug Administration for the treatment of psoriasis [29] [30] [31] and psoriatic arthritis.
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Efficacy studies, including any comparative studies
The first study evaluating ustekinumab in CD was published in 2008. 26 The multicenter trial included two populations. Population 1 included 104 patients with moderate-to-severe CD enrolled in a double-blind, placebo-controlled, parallelgroup, crossover study. Patients were randomized into one of four groups: SC placebo at weeks 0, 1, 2, and 3, then 90 mg ustekinumab at weeks 8, 9, 10 and 11; SC 90 mg ustekinumab at weeks 0, 1, 2, and 3, then placebo at weeks 8, 9, 10, and 11; IV placebo at week 0, then 4.5 mg/kg ustekinumab at week 8; or IV 4.5 mg/kg ustekinumab at week 0, then placebo at week 8. Population 2 comprised 27 patients who were either nonresponders to a three-dose infliximab 5 mg/kg induction (primary nonresponders) or initial responders who lost response during maintenance therapy every 8 weeks (secondary nonresponders). Population 2 patients were enrolled in an open-label study, and were randomized to either SC 90 mg ustekinumab at weeks 0, 1, 2, and 3 or IV 4.5 mg/kg ustekinumab at week 0. The primary end point, a reduction of at least 25% and 70 points from the baseline CD Activity Index (CDAI) at week 8 in population 1, was not met in this study; clinical response was achieved in 25 of 51 patients (45%) in the combined ustekinumab group compared to 21 of 53 patients (40%) in the placebo group at week 8 (P=0.34). However, in a subgroup analysis of 49 patients previously treated with infliximab, the rates of clinical response to ustekinumab were significantly greater than those for placebo through 8 weeks (Figure 1 ).
The high placebo-response rate in this study is notable, as it impacts the ability to detect an overall treatment effect for ustekinumab. For population 2, numerically higher rates of clinical response and remission were seen with IV administration of ustekinumab compared to SC administration out to week 8, 26 but this did not achieve statistical significance. The results of a Phase IIB 36-week, randomized, double-blind, placebo-controlled trial of ustekinumab in CD were reported in 2012. 16 The study population comprised 526 patients with moderate-to-severe CD who were previously resistant to TNFα inhibitors. TNFα resistance was defined as a primary nonresponse, secondary nonresponse, or unacceptable side effects after receiving a TNFα antagonist at an approved dose.
During the 8-week induction phase, patients were randomly assigned to ustekinumab 1, 3, or 6 mg/kg IV or placebo. At week 8, ustekinumab responders and nonresponders underwent a separate randomization to receive either SC ustekinumab 90 mg or placebo at weeks 8 and 16. Likewise, patients who responded to placebo induction received SC placebo at weeks 8 and 16, while patients who did not respond to placebo induction received SC ustekinumab 270 mg at week 8 followed by SC ustekinumab 90 mg at week 16. Efficacy was then assessed for all patients -ustekinumab responders and nonresponders as well as placebo responders and nonresponders -at week 22, and all patients were followed through week 36 for safety analysis. The primary end point was a clinical response (.100-point decrease from baseline CDAI) at week 6.
The primary study end point was achieved in significantly more patients who received 6 mg/kg of IV ustekinumab at 6 weeks compared to those who received placebo (39.7% versus 23.5%, P=0.005). The difference was not statistically significant with the 3 mg/kg ustekinumab dose (34.1% versus 23.5%, P=0.06) and there was not a clear dose response (Figure 2) . The proportion of patients in clinical remission (CDAI score ,150) at weeks 6 and 8 was not significantly different between patients treated with ustekinumab and those treated with placebo (12.2% in the 6 mg/kg ustekinumab versus 10.6%, P=0.68 at week 6; and 18.3% versus 10.6%, P=0.07 at week 8). The median baseline CDAI score was 333. This high numeric value at baseline likely impacted the ability to achieve clinical remission by week 8 in the study. Of the patients who responded to ustekinumab induction, the proportion of patients with maintained response at 22 weeks was significantly greater in the ustekinumab group compared to the placebo group (69.4% versus 42.5%, P,0.001). There were also significantly higher rates of clinical remission at week 22 with ustekinumab (41.7% versus 27.4%, P=0.03) (Figure 3 ).
Three additional trials involving ustekinumab in CD are currently being performed ( 
Safety and tolerability
Safety data for ustekinumab are available for more than 3,000 patients enrolled in clinical trials evaluating use of the drug in psoriasis, psoriatic arthritis, multiple sclerosis, and CD. 19 In the two published CD trials, the proportion of patients with at least one adverse event through week 8 was slightly higher in the placebo group (Phase IIA) and similar among the study groups (Phase IIB). 16, 26 In the Phase IIA study in CD, serious adverse events occurred in three of 53 patients (6%) in the placebo group compared to two of 51 patients (4%) in the ustekinumab group through week 8. No serious infections or opportunistic infections were reported during this time. Twelve patients (23%) in the placebo group experienced one or more infections compared to eight patients (15%) in the ustekinumab group. 26 Administration-site reactions occurred more commonly in the SC placebo group (4%) than the SC ustekinumab group (0%). 26 Mild adverse events occurring within 1 hour of IV administration, including fever, flushing, and pruritus, were more common in the IV ustekinumab group (19%) compared to the IV placebo group (0%). 26 Adverse events were recorded through 28 weeks, and six patients (6%) in population 1 experienced one or more serious adverse events (worsening CD in two patients, small intestinal obstruction in two patients, colonic stenosis and pneumothorax in one patient, and prostate cancer in one patient), and four patients (15%) in population 2 experienced one or more serious adverse events (viral gastroenteritis in one patient, worsening CD in one patient, nephrolithiasis in one patient, and worsening CD, syncope, and disseminated histoplasmosis in one patient). The histoplasmosis occurred in a patient who had discontinued infliximab 10 mg/kg 3 months prior to study Clinical remission
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Proportion of patients (%) Figure 3 Clinical remission in anti-tumor necrosis factor-α-exposed Crohn's patients with an initial response to ustekinumab. 
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Ustekinumab in moderate-severe Crohn's disease entry, and received IV ustekinumab, azathioprine, and prednisone concomitantly. 26 Two population 1 patients developed malignancy: prostate cancer was diagnosed 2 months after receiving IV ustekinumab in a patient with elevated prostatespecific antigen levels prior to enrollment, and squamous and basal skin cancers were diagnosed in a patient approximately 6 months after SC ustekinumab. 26 No tuberculosis or hematologic malignancies were reported during the study. 24 In the Phase IIB study, serious infections occurred in five patients who received 6 mg/kg ustekinumab (Clostridium difficile, viral gastroenteritis, urinary tract infection, anal abscess, and vaginal abscess), in one patient who received 1 mg/kg of ustekinumab (central line staphylococcal infection), and in one patient who received placebo (anal abscess) during the 8-week induction phase. 16 Patients were followed for approximately 25 weeks in the maintenance phase, with similar reported rates of serious adverse events as seen in the ustekinumab and placebo groups. No deaths, major cardiovascular events, tuberculosis, or other serious opportunistic infections were reported. 16 One patient treated with 1 mg/kg IV ustekinumab followed by 90 mg SC ustekinumab at weeks 8 and 16 developed a basal cell carcinoma. 16 There were no other malignancies reported during the study.
While safety data in the CD population have thus far only been reported through 28 weeks of follow-up, long-term data are available from trials of ustekinumab in patients with psoriasis. The longest follow-up was 5 years in patients with moderate-to-severe psoriasis in PHOENIX 1 (A Study of Safety and Effectiveness of Ustekinumab [CNTO 1275] in Patients with Moderate to Severe Plaque-Type Psoriasis). 30 Similar to studies in CD, most reported adverse events with ustekinumab were mild and did not require treatment withdrawal. The long-term safety of ustekinumab was recently studied in a pooled analysis of psoriasis trials involving 1,852 patients exposed to ustekinumab for at least 1 year, 1,247 patients for at least 2 years, and 157 patients for at least 3 years. 19, 37, 38 Common adverse events seen with longterm use were similar to those reported during the placebocontrolled period, and included headache, nasopharyngitis, and upper respiratory tract infections ( Table 2 ). The most frequent serious adverse events reported with long-term use were serious infections. Rates were similar between the placebo and 90 mg groups and lower in the 45 mg group (rates of 0.49 and 1.97 events per 100 patient-years in the 45 mg and 90 mg ustekinumab groups, respectively, compared to 1.70 in the placebo group). 19, 38 No cases of tuberculosis were reported. 37, 38 The second-most common serious adverse events reported were cardiac in nature (rates of 0.8 and 1.3 events per 110 patient-years in the 45 mg and 90 mg, ustekinumab groups, respectively). 19 The incidence of malignancy (excluding nonmelanoma skin cancers) was comparable between patients exposed to ustekinumab and the general US population (rates of 0.7 and 0.5 events per 100 patient-years in the 45 mg and 90 mg ustekinumab groups, respectively). 19, 38 Most recently, results from a pooled analysis of four studies of ustekinumab in psoriasis followed safety data up to 5 years after treatment. 39 As previously reported, no doserelated or cumulative toxicity was observed with increasing duration of ustekinumab administration for up to 5 years. 39 In the Phase IIA ustekinumab study, 99 of 131 patients had serum samples available for assessment of ustekinumab antibodies. No anti-ustekinumab antibodies were identified in this study. 24 In the Phase IIB ustekinumab study, 427 patients treated with ustekinumab had samples for analysis of immunogenicity. Three patients (0.7%) had positive antibodies to ustekinumab through week 36. 16 Higher rates of antibodies to ustekinumab were reported in the pooled data from four studies of ustekinumab in psoriasis, which comprised 3,117 patients treated with ustekinumab, ranging from 3.8% to 5.4%. 39 There are currently no data on the use of concurrent immunomodulators and the rate of antibody formation to ustekinumab.
Patient-focused perspectives, such as quality of life, satisfaction, adherence, and update
To date, there are no specific data available regarding QOL in patients with CD who are treated with ustekinumab. The effect of ustekinumab on health-related QOL was evaluated as a secondary end point in some psoriasis and psoriatic arthritis trials. 19 In the clinical trials in patients with psoriasis, ustekinumab significantly improved healthrelated QOL, as assessed by the Dermatology Life Quality Index at 12 weeks. 30, 31 Work productivity, number of work days missed, symptoms of depression and anxiety, and sexual difficulties were also improved in the ustekinumabtreatment group. [40] [41] [42] Improvements in health-related QOL were also seen in patients with psoriatic arthritis treated with ustekinumab. 
Conclusion

Potential place in therapy
Currently, anti-TNFα antagonists are the most effective therapeutic options available for patients with CD, and have the potential to induce and maintain steroid-free remission, promote mucosal healing, and modify the natural course of the disease. However, a significant proportion of patients do not respond adequately to these agents, and an additional subset of patients develop side effects that require changing to a different therapeutic class. Therefore therapies inhibiting inflammation through mechanisms other than TNFα blockade are needed.
IL-12 and IL-23 are important proinflammatory cytokines involved in the pathogenesis of CD, and therefore targeting IL-12/23 should reduce proinflammatory cytokine production and reduce intestinal inflammation in this setting. Data from the published Phase II trials evaluating ustekinumab in CD are promising, and have shown that ustekinumab is effective in inducing clinical response and maintaining clinical response and clinical remission in moderate-to-severely active CD in patients with a prior inadequate response to anti-TNFα therapy. It is currently unclear whether ustekinumab is effective in CD patients naïve to anti-TNFα therapies. The only published study that included this patient population failed to meet its primary end point of clinical response. This study was limited by a high placebo-response rate (40%) which limits the ability to detect a treatment effect for ustekinumab. Furthermore, a second anti-IL-12/23 antibody, briakinumab, was unable to show convincing clinical benefit in a similar CD patient population, 43 and is no longer in clinical development. Therefore, while ustekinumab has shown benefit in patients with prior anti-TNFα exposure, it is not completely certain how ustekinumab will be placed in the treatment paradigm for CD or how effective it will be in anti-TNFα-naïve patients (Table 3) .
Future role
We suspect that ustekinumab will be shown to be effective at inducing and maintaining remission in patients with moderate-to-severely active CD with a prior inadequate response to anti-TNFα therapy. We also suspect that ustekinumab will be an appropriate first-line biologic option in patients with a contraindication to anti-TNFα agents, such as those with multiple sclerosis. It is currently unclear whether ustekinumab will be effective in patients naïve to anti-TNFα therapies. The results from Phase III trials of ustekinumab will help address these questions.
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